Consistency with treatment, healthy eating, and patience are key to experiencing the full results of Semaglutide GLP-1 therapy
doi: 10.1210/en.2011-1443 33 DicksonSLShiraziRHHanssonCBergquistFNissbrandtHSkibickaKP
Phase 2a trial of GSBR-1290 (45mg and 90mg) in 54 T2DM patients over 12 weeks observed significant reduction in HbA1c (45 mg: -1.01%, p=0.008

Acceptable Documentation Sources Medication reconciliation list showing insulin as an active current medication Provider note explicitly stating patient is on long-term insulin therapy or insulin-controlled Type 2 diabetes Prescription record for insulin within the encounter date or active medication review Problem list entry indicating insulin-dependent or insulin-controlled diabetes What Documentation Is Insufficient A history of insulin use without confirmation it is ongoing at this encounter A notation that insulin was administered during the encounter without evidence of an ongoing regimen Discharge summary from a prior hospitalization only, with no current medication confirmation Practices that use digital intake forms can embed medication status prompts that capture insulin use at every visit check-in, creating a structured data point in the record without requiring the provider to manually note it in the encounter documentation

How Serena Williams admission of using a GLP-1 drug could impact the stigma of obesity Serena Williams GLP-1 disclosure may shift obesity conversations, though treatment requires a holistic approach, Northeastern experts say
The arms differed in what was added on top: 1 The doublet combinations (trevogrumab added to semaglutide) preserved roughly half the lean mass that would otherwise have been lost